LEI: 549300Q7EXQQH6KF7Z84
2 July 2024
RTW Biotech Opportunities Ltd
New Investments in Mirador Therapeutics & Santa Ana Bio
RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note investments in new private portfolio companies, Mirador Therapeutics ("Mirador") and Santa Ana Bio ("Santa Ana").
The Company, alongside other investment vehicles managed by RTW Investments, LP (the "Investment Manager"), participated in Mirador's Series A financing round that raised over $400 million for its launch in March.
Mirador Therapeutics is a next-generation precision medicine company focused on immunology and inflammation. The company's Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases.
Josh Kennedy-Smith, Partner and Research Analyst at the Investment Manager said, "We are thrilled to support Mirador Therapeutics whose team we worked with when they led Prometheus Biosciences through to its acquisition by Merck for $10.8 billion in 2023. We have every confidence in their track record to develop the next wave of precision medicines in immunology and inflammation."
The Company, alongside other investment vehicles managed by the Investment Manager, also participated in Santa Ana's Series A financing round that raised $168 million in May.
Santa Ana Bio is a biotechnology company developing a pipeline of innovative therapeutics and leveraging its multi-omics platform to unlock the full potential of precision medicines. Santa Ana's platform, based on transcriptomics and proteomics, addresses the limitations of today's commercial therapeutics.
Josh Kennedy-Smith said, "We're excited to support Santa Ana as they advance their broad pipeline of precision, next-generation antibodies for autoimmune diseases into clinical development."
Commenting on recent activity, Chief Investment Officer, Rod Wong, said, "We are active again in private investing and seeing a lot of opportunity. After a couple of years of slower deployment as we focused on opportunities in the public market, we now expect to head back to our normal pace of about a dozen private deals per year, especially if the IPO window continues to trend positively."
The full text of these portfolio company announcements can be accessed here: https://santaanabio.com/.
For Further Information
| RTW Investments, LP | +44 20 7959 6361 |
| Woody Stileman, Managing Director, Business Development Krisha McCune, Director, Investor Relations | |
|
|
|
|
Buchanan (PR & Communications Adviser) |
+44 20 7466 5107 |
| Charles Ryland |
|
| Henry Wilson |
|
| George Beale |
|
|
|
|
| Deutsche Numis (Joint Corporate Broker) | +44 20 7260 1000 |
| Freddie Barnfield |
|
| Nathan Brown |
|
| Euan Brown |
|
| |
|
| BofA Securities (Joint Corporate Broker) | +44 20 7628 1000 |
| Edward Peel |
|
| Alex Penney |
|
|
Cadarn Capital (Distribution & IR Partner) |
+44 73 6888 3211 |
| David Harris |
|
|
Elysium Fund Management Limited Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director
|
+44 14 8181 0100 |
| Morgan Stanley Fund Services USA LLC | +1 914 225 8885 |
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.
***********
The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.
The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.
***********
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.